Taysha Gene Therapies Inc [TSHA] stock is trading at $4.96, up 1.02%. An important factor to consider is whether the stock is rising or falling in short-term value. The TSHA shares have gain 4.42% over the last week, with a monthly amount glided 1.64%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Taysha Gene Therapies Inc [NASDAQ: TSHA] stock has seen the most recent analyst activity on October 21, 2025, when Raymond James initiated its Strong Buy rating and assigned the stock a price target of $13. Previously, BofA Securities started tracking the stock with Buy rating on July 11, 2025, and set its price target to $8. On June 27, 2024, BMO Capital Markets initiated with a Outperform rating and assigned a price target of $5 on the stock. Piper Sandler started tracking the stock assigning an Overweight rating and suggested a price target of $9 on April 09, 2024. Jefferies downgraded its rating to a Hold and reduced its price target to $1.50 on February 01, 2023. Morgan Stanley downgraded its rating to Equal-Weight for this stock on January 27, 2023, and downed its price target to $3. In a note dated November 09, 2022, Goldman downgraded a Neutral rating on this stock and revised its target price from $16 to $3.
Taysha Gene Therapies Inc [TSHA] stock has fluctuated between $1.05 and $5.51 over the past year. Currently, Wall Street analysts expect the stock to reach $11 within the next 12 months. Taysha Gene Therapies Inc [NASDAQ: TSHA] shares were valued at $4.96 at the most recent close of the market. An investor can expect a potential return of 121.77% based on the average TSHA price forecast.
Analyzing the TSHA fundamentals
Taysha Gene Therapies Inc [NASDAQ:TSHA] reported sales of 8.10M for the trailing twelve months, which represents a growth of 78.60%. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -11.61%, Pretax Profit Margin comes in at -11.45%, and Net Profit Margin reading is -11.45%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.8 and Total Capital is -0.31. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.81 points at the first support level, and at 4.65 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.16, and for the 2nd resistance point, it is at 5.35.
Ratios To Look Out For
For context, Taysha Gene Therapies Inc’s Current Ratio is 12.48. On the other hand, the Quick Ratio is 12.48, and the Cash Ratio is 12.34. Considering the valuation of this stock, the price to sales ratio is 167.04, the price to book ratio is 5.44.
Transactions by insiders
Recent insider trading involved Rumana Haque-Ahmed, Officer, that happened on Sep 22 ’25 when 10770.0 shares were purchased. President and Head of R&D, Nagendran Sukumar completed a deal on Sep 10 ’25 to sell 0.2 million shares. Meanwhile, Officer Nagendran Sukumar bought 0.2 million shares on Sep 10 ’25.
